Citation Export
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jae Seong | - |
dc.contributor.author | Kildegaard, Helene Faustrup | - |
dc.contributor.author | Lewis, Nathan E. | - |
dc.contributor.author | Lee, Gyun Min | - |
dc.date.issued | 2019-09-01 | - |
dc.identifier.issn | 1879-3096 | - |
dc.identifier.uri | https://aurora.ajou.ac.kr/handle/2018.oak/30645 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063035419&origin=inward | - |
dc.description.abstract | Mammalian expression platforms are primary production systems for therapeutic proteins that require complex post-translational modifications. Current processes used for developing recombinant mammalian cell lines generate clonal cell lines with high phenotypic heterogeneity, which has puzzled researchers that use mammalian cell culture systems for a long time. Advances in mammalian genome-editing technologies and systems biotechnology have shed light on clonal variation and enabled rational cell engineering in a targeted manner. We propose a new approach for a next-generation cell line development platform that can minimize clonal variation. Combined with the knowledge-based selection of ideal integration sites and engineering targets, targeted integration-based cell line development will allow tailored control of recombinant gene expression with predicted phenotypes. | - |
dc.description.sponsorship | This work was supported in part by the Novo Nordisk Foundation ( NNF10CC1016517 ) and the NRF funded by the Korean government ( 2018R1C1B6001423 ). The authors declare no competing financial interests. | - |
dc.description.sponsorship | This work was supported in part by the Novo Nordisk Foundation (NNF10CC1016517) and the NRF funded by the Korean government (2018R1C1B6001423). The authors declare no competing financial interests. | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier Ltd | - |
dc.subject.mesh | Cell lines | - |
dc.subject.mesh | Clonal variations | - |
dc.subject.mesh | Development platform | - |
dc.subject.mesh | Mammalian cell culture | - |
dc.subject.mesh | Mammalian cell lines | - |
dc.subject.mesh | Post-translational modifications | - |
dc.subject.mesh | Recombinant gene expressions | - |
dc.subject.mesh | Transgene | - |
dc.subject.mesh | Animals | - |
dc.subject.mesh | Cell Engineering | - |
dc.subject.mesh | Cell Line | - |
dc.subject.mesh | Gene Editing | - |
dc.subject.mesh | Genetic Engineering | - |
dc.subject.mesh | Mammals | - |
dc.subject.mesh | Recombinant Proteins | - |
dc.title | Mitigating Clonal Variation in Recombinant Mammalian Cell Lines | - |
dc.type | Article | - |
dc.citation.endPage | 942 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 931 | - |
dc.citation.title | Trends in Biotechnology | - |
dc.citation.volume | 37 | - |
dc.identifier.bibliographicCitation | Trends in Biotechnology, Vol.37 No.9, pp.931-942 | - |
dc.identifier.doi | 10.1016/j.tibtech.2019.02.007 | - |
dc.identifier.pmid | 30898338 | - |
dc.identifier.scopusid | 2-s2.0-85063035419 | - |
dc.identifier.url | www.elsevier.com/locate/tibtech | - |
dc.subject.keyword | cell line development | - |
dc.subject.keyword | clonal variation | - |
dc.subject.keyword | rational cell engineering | - |
dc.subject.keyword | transgene integration | - |
dc.type.other | Review | - |
dc.identifier.pissn | 0167-7799 | - |
dc.description.isoa | false | - |
dc.subject.subarea | Biotechnology | - |
dc.subject.subarea | Bioengineering | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.